ASCO 2025: Amgen’s Imdelltra Cuts Small Cell Lung Cancer Death Risk by 40% Versus Chemo

At ASCO 2025, Amgen presented late-breaking Phase 3 data showing IMDELLTRA (tarlatamab-dlle) reduced the risk of death by 40% compared to standard-of-care chemotherapy in patients with small cell lung cancer (SCLC) who had progressed after one line of platinum-based chemotherapy5.

Median overall survival (OS) in the IMDELLTRA group was 13.6 months versus 8.3 months for chemotherapy, offering a survival benefit of more than five months (hazard ratio [HR] 0.60; 95% CI:
0.47, 0.77; P < 0.001)5.

These results were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (LBA8008) and published in The New England Journal of Medicine5.

IMDELLTRA represents a potential new treatment paradigm for SCLC, which is known for being aggressive and difficult to treat, especially in the relapsed/refractory setting5.

Sources:

5. https://www.prnewswire.com/news-releases/imdelltra-significantly-reduced-risk-of-death-by-40-in-small-cell-lung-cancer-patients-302470647.html